Ciwon daji na neuroendocrine na Pancreatic (NETs) yawanci suna girma a hankali, kuma dakin gwaje-gwaje na lura da ƙari don alamun girma ta hanyar gwajin hoto. Marasa lafiya tare da NET suna yadawa daga cikin pancreas yawanci suna da alamun bayyanar cututtuka kamar zawo ko matsalolin hormonal. Ana iya amfani da su don magunguna irin su octreotide, lanreotide, diazoxide, da proton pump inhibitors, wanda zai iya hana ci gaban ƙari.
When the patient’s symptoms cannot be controlled or the scan shows signs of tumo growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
If all feasible treatments no longer work, then consider participating in clinical trials to test new therapies. Participation in clinical trials is likely to benefit some patients.
